General Biotechnology

Biopharma vendors: the tender isn’t the deal—your timing is.
Drug patent cliffs don’t just reshape pipelines. They reshape procurement. And if you sell into EU markets—especially with tender strategy consulting—your competitive edge is less about pit…

Pharma doesn’t always “invent” new drugs. Sometimes it simply re-labels old molecules—and monetizes them like they’re new.
That’s the uncomfortable truth behind a growing playbook: take a mature drug, find a fresh indication, tweak the evidence, and—if…

Biopharma is entering a new kind of “cliff”—not just the loss of exclusivity, but the scramble to protect revenue when generics and authorized copies arrive faster than brand teams can repackage the story.
Here’s the agitation: most companies still tre…

Most pharma teams don’t lose patent value because they can’t innovate—they lose it because they pick the wrong patent to extend.
That sounds harsh, but it’s the reality behind “one-shot” patent strategy: when you’re trying to maximize the incremental v…

Drug patent litigation isn’t just about what’s claimed—it’s about what’s designed around.
In the pharmaceutical world, “design around” sounds like a strategy. In practice, it’s a discipline: a way of reading formulation patent claims like a map, then…

Pharma has a $300 billion question it can’t afford to misread: Is it “patent term restoration” or “patent term adjustment”—and what does it mean for your pipeline, your pricing power, and your next 5–10 years of cash flow?
That’s the subtext behind a t…

Pharmaceutical patent strategy is often discussed like a binary choice: cut losses or keep fighting.
But the real question isn’t whether a patent is “good” or “bad.” It’s whether your portfolio is built to win—or whether it’s quietly turning into an ex…

The clock is already ticking—so why are so many commercial market access teams waiting until it’s too late?
In pharma, timing isn’t just a competitive advantage. It’s the difference between capturing value and watching it evaporate.
Drug patent cliffs …

Before You Launch: The Freedom-to-Operate (FTO) Checklist That Can Save Your Next Product
In pharma, the hardest part of “innovation” isn’t the science—it’s the legal reality that follows it.
A promising molecule can clear clinical hurdles, win payer i…

Pharma procurement teams are sitting on a quiet risk radar—and most of them never turn it on.
Paragraph IV filings are often treated like a legal event: something for counsel to track, something for business development to react to, something for finan…